Navigation Links
Mayo Clinic-led study: 2 drugs do not improve kidney function in acute heart failure patients
Date:11/18/2013

DALLAS -- Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.

In the Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF) randomized 26-site trial in the U.S. and Canada, researchers analyzed data on 360 hospitalized acute heart failure patients with kidney dysfunction from September 2010 to March 2013. Compared to placebo, researchers found that neither dopamine nor nesiritide, when also used with diuretic (water pills) therapy, was better at increasing urine volume or improving levels of serum cystatin-C, an indicator of kidney function, at the end of a 72-hour treatment.

"Kidney-enhancing therapies in acute heart failure continue to elude us," says Horng Chen, M.B., B.Ch., lead author and Mayo Clinic cardiologist. "In the past five years, all the major acute heart failure therapeutic clinical trials have not demonstrated beneficial effects of the therapies tested. This could be partly because the definition of acute heart failure is broad, and hence it includes a diverse group of patients."

Therefore, one take-away from the results of ROSE-AHF is that future studies in acute heart failure may need to target specific subgroups of these patients. For example, some patients have preserved ejection fraction, where the heart's lower chambers are stiff and cannot relax enough to fill fully between beats, and others may have reduced ejection fraction, where the heart is weak, Dr. Chen says.

Heart failure occurs when the heart doesn't pump blood as well as it should. Acute heart failure -- when heart failure patients require hospitalization -- is the most common cause of hospitalization in patients 65 years and older in the U.S., according to the American Heart Association.

"The study shows that as a one-size-fits-all therapy for acute heart failure patients with renal dysfunction, neither dopamine nor nesiritide improved the ability to get rid of excess fluid while protecting the kidneys in patients hospitalized for heart failure," says senior author Margaret Redfield, M.D., Mayo Clinic cardiologist. "The ROSE-AHF study suggests that these two drugs may have different effects in different types of heart failure. Future heart failure studies need to carefully assess the effect of therapies in specific types of patients as drugs may help some patients and not others."


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-990-1182
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic-led study unravels biological pathway that controls the leakiness of blood vessels
2. Ability to metabolize tamoxifen affects breast cancer outcomes, Mayo Clinic-led study confirms
3. Mayo Clinic-led study identifies biomarkers for early risk assessment of acute kidney injury
4. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
5. Study: Insomnia takes toll on tinnitus patients
6. Study: No link between depression, nasal obstruction
7. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
8. Study: Kids Who Sleep in Parents Bed Less Likely to Be Overweight
9. OHSU study: Misdiagnosis of MS is costing health system millions per year
10. UW study: Sleep apnea associated with higher mortality from cancer
11. Study: Heart damage after chemo linked to stress in cardiac cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... ... pleased to announce the release of the third edition of The Gift of ... guide for patients, caregivers and families to navigate the clinical research process. The ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... several first-in-human studies on the detection and treatment of infectious diseases at ... these ground-breaking studies were noninvasive detection of residual HIV infected cell persistence ...
(Date:9/11/2019)... MEADVILLE, Pa. (PRWEB) , ... September 12, 2019 , ... ... of living with diagnosed coronary artery disease as he hopes to prevent anyone from ... the creation of published author John Saltwick, a writer who was diagnosed with coronary ...
(Date:9/11/2019)... TAMPA, Fla. (PRWEB) , ... September 11, 2019 ... ... Medical Academy (UMA) and an accredited continuing medical education (CME) provider, is the ... that capacity, Global reviewed presentations, vetted speakers, and screened topics, as it has ...
(Date:9/11/2019)... ... September 11, 2019 , ... RMA of Connecticut , ... their family, will host a free informational event that will demystify fertility age-related issues ... voucher for the first fifty registrants. The event, “What’s Your Real Fertility Age,” will ...
Breaking Medicine News(10 mins):
(Date:9/17/2019)... ... ... 6th year in a row, Mental Health America (MHA) released its annual ... Columbia based on several mental health and access measures. This year, Pennsylvania came out on ... the trends of the last 6 years and shows that many are still not receiving ...
(Date:9/17/2019)... ... ... Embr Labs , the breakthrough thermal technology company and creator of the ... Partners, with participation from Safar Partners, Joyance Partners , Bose Ventures , ... in wellness and digital therapeutics, accelerate development for the next generation of its core ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... joined the esteemed Haute Beauty network. , The Haute Beauty Network, well known ... Dr. Babis Rammos as a body expert and our newest addition to the ...
Breaking Medicine Technology: